A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621 a Novel Biologic Targeting CD47 in Subjects with Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors | NYU Langone Health

Go Back to All Clinical Trials

A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621 a Novel Biologic Targeting CD47 in Subjects with Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Relapsed Or Refractory Hematologic Malignancies And Selected Solid Tumors
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:

1. Advanced measurable malignancy 2. Relapsed or refractory disease that has previously progressed on, or is currently progressing on standard anticancer therapy or for whom no other approved conventional therapy exists

You may not be eligible for this study if the following are true:

1. Acute Myeloid Leukemia (AML) M3 2. Known, current central nervous system disease involvement or untreated brain metastases 3. Prior anti-CD47 therapy, with the exception of prior TTI-621 therapy